<DOC>
	<DOC>NCT01861444</DOC>
	<brief_summary>This prospective, multicenter, observational study will assess the prevalence of chronic hepatitis D in patients with chronic hepatitis B in Romania and evaluate the efficacy of Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis D. Eligible patients treated with Pegasys according to current medical practice will be followed until 24 weeks after the end of treatment.</brief_summary>
	<brief_title>An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For epidemiological part of the study: Adult patients &gt;/= 18 years of age Positive HBsAg for at least 6 months For the noninterventional section of the study Adult patients, &gt;/= 18 years of age Positive HBsAg for at least 6 months Positive antidelta and positive HDV RNA by PCR Elevated serum ALT &gt;/= 2x ULN Patients with any of the following will not be eligible for treatment with Pegasys: History of neurological disease History of severe psychiatric disease Decompensated diabetes History of immunologically mediated disease History of severe cardiac disease History or other evidence of severe chronic pulmonary disease Inadequate hematologic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>